SHORT COMMUNICATION

Diagnosis and treatment of influenza based on health insurance claims between the 2010–2011 and 2019–2020 influenza seasons in Japan

Eiko Shimizu1 | Kosuke Iwasaki1,2 | Yoshie Hongo1,3 | Manami Yoshida3 | Masahiro Kinoshita3 | Shinzo Hiroi1,3 | Daisuke Tamura4

1Social Cooperation Program of IT Healthcare, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
2Milliman Inc., Tokyo, Japan
3Medical Affairs Department, Integrated Disease Care Division, Shionogi & Co., Ltd., Tokyo, Japan
4Department of Pediatrics, Jichi Medical University, Tochigi, Japan

Correspondence
Yoshie Hongo, Medical Affairs, Shionogi & Co., Ltd. 7F, Tekko Building, 1-8-2, Marunouchi, Chiyoda-ku, Tokyo 100-0005, Japan.
Email: yoshie.hongo@shionogi.co.jp

Funding information
Shionogi & Co., Ltd.

Abstract
Medical practices for influenza virus infection vary among countries. In Japan, treatment with anti-influenza drugs is recommended for patients diagnosed with influenza. This health claims database study provides quantitative information aimed at describing the actual medical practices, including diagnostic testing and medication use, for managing influenza in Japan. Most patients diagnosed with influenza underwent diagnostic tests and were prescribed anti-influenza drugs. Meanwhile, the majority of patients prescribed anti-influenza drugs had undergone diagnostic testing. However, an increase in the percentage of anti-influenza prescriptions without diagnostic testing was observed during the 2019–2020 influenza season, which may be associated with the COVID-19 pandemic.

KEYWORDS
antiviral agents, COVID-19, diagnosis, diagnostic tests, healthcare administrative claims, influenza

1 | INTRODUCTION

Although influenza virus infection is self-limiting in most patients, it is an important disease that affects many people and causes severe symptoms in some cases. In Japan, the epidemic occurs mainly during winter, and the cumulative seasonal number of influenza patients is approximately 5%–15% of the population.1 Influenza can cause complications such as influenza-associated encephalopathy in infants and young children and pneumonia in the elderly.2,3

Medical practices for influenza vary among countries, although rapid diagnosis and clinical management reduce the incidence of severe illness and complications.4 In Japan, treatment with anti-influenza drugs is recommended for patients who were confirmed or suspected of having influenza by the Japanese Association for Infectious Diseases (JAID).5 A rapid diagnostic test is usually performed for suspected cases, but the sensitivity varies depending on time between symptom onset and presentation.6 Consequently, influenza diagnosis may not always be based solely on test results but can instead be comprehensively determined based on symptoms and disease prevalence.

Quantitative information about medical practices for influenza, including diagnostic testing, diagnosis, and treatment, is not well provided in Japan, although the epidemic status of seasonal influenza has been reported by surveillances,2,7,8 and a high prescription rate (98.4%) for hospitalized child patients during the 2009 influenza A (H1N1) pandemic has been reported by a chart review study.7 Furthermore, medical practices may have changed due to the coronavirus disease 2019 (COVID-19) pandemic. Therefore, this study analyzed insurance claims databases to show the quantitative information about medical practices for influenza between the 2010–2011 and 2019–2020 seasons and better understand the medical handling of influenza in Japan.
A claims database of Japanese health insurance associations, provided by JMDC Inc., contains data of employees and their family members obtained from companies belonging to these associations, which corresponded to approximately 6% of the Japanese population as of August 2020. The percentage of males is higher than that of females, people aged ≥65 years are few (those aged 70–74 are <1% of the members), and those aged ≥75 years are excluded. The database includes the daily records of medical practices, including diagnostic tests, treatments, and monthly diagnostic records. All records associated with remuneration can be traced for each individual, regardless of medical institution type. Results of diagnostic tests are not included.

This study used descriptive statistics. We analyzed patient numbers and the distribution of combination patterns of diagnostic tests (hereafter tests), diagnoses, and prescriptions for anti-influenza medications throughout each season. We also analyzed weekly numbers of tests and prescriptions. The study period was from September 2010 to April 2020 and was divided by each influenza season, starting from September 1 of a current year and ending on August 31 of the following year (total, 52 weeks). The 2019–2020 season (2019/2020) lasted until April 2020. Tests were defined as a “qualitative influenza virus antigen test”; the diagnoses included definitive diagnoses coded as J09, J10, or J11 by the International Statistical Classification of Diseases and Related Health Problems (10th revision); prescriptions included the following anti-influenza drugs: oseltamivir phosphate, zanamivir hydrate, baloxavir marboxil, peramivir hydrate, or laninamivir octanoate hydrate. We defined all anti-influenza drug prescriptions as those indicated for the treatment of influenza because prophylactic prescriptions were not covered by Japanese health insurance.

We used the SAS software package, version 9.4 (SAS Institute, Cary, NC, USA) and Microsoft Excel 365 (Microsoft, Redmond, WA, USA) for data analysis.

### RESULTS

The percentage of patients with records of tests, diagnoses, or prescriptions for influenza was 11.0% of the population in 2012/2013—the lowest during the study period (Table 1). In 2017/2018 and 2018/2019, the percentage was the highest, almost 20% in both the seasons. Among the combination patterns, the test + diagnosis + prescription combination was the most frequent, followed by test alone until 2018/2019, but test alone was the most frequent (55.2%) in 2019/2020 (Figure 1A). Among patients with a diagnosis, ≥90% took the test (Figure 1B) and ≥90% received prescriptions (Figure 1C) during all seasons.

In the last four seasons, the number of patients who had either a test or prescription was the highest during the 21st or 22nd week for three consecutive seasons from 2016/2017 and in the 17th week in 2019/2020 (Figure S1). Among the combination patterns, the test + prescription combination was approximately 50%–60% around the week with the highest number of patients, and test alone was the

### TABLE 1

The number and demographics (average and standard deviation) of individuals in the population in the database and percentage of patients who received a test, diagnosis, or prescription for influenza infection in each influenza season

| Season       | Number of individuals in the population | Age (average) | Age (SD) | Female (%) | Patients with test, diagnosis or prescription (%) |
|--------------|----------------------------------------|---------------|----------|------------|-----------------------------------------------|
| 2010/2011    | 1,317,567                               | 31.4          | 17.9     | 44%        | 13.5                                          |
| 2011/2012    | 1,765,080                               | 32.0          | 18.2     | 44%        | 14.9                                          |
| 2012/2013    | 2,771,476                               | 32.1          | 18.3     | 44%        | 15.0                                          |
| 2013/2014    | 4,113,690                               | 33.1          | 18.5     | 45%        | 15.7                                          |
| 2014/2015    | 5,149,566                               | 33.4          | 18.6     | 45%        | 15.9                                          |
| 2015/2016    | 6,116,093                               | 33.5          | 18.7     | 46%        | 16.0                                          |
| 2016/2017    | 7,179,776                               | 33.7          | 18.8     | 46%        | 16.1                                          |
| 2017/2018    | 7,457,659                               | 33.7          | 18.8     | 45%        | 16.2                                          |
| 2018/2019    | 6,722,866                               | 33.7          | 18.8     | 46%        | 16.3                                          |
| 2019/2020    | 6,722,866                               | 33.7          | 18.8     | 46%        | 16.3                                          |

Abbreviation: SD, standard deviation.
highest in the other weeks (Figures 2 and S1). Prescription alone was <5% in most weeks. In particular, the percentage of prescription alone was low during the weeks when the number of patients was small with a high percentage of test alone, and the percentage was high when the number of patients was large with a high percentage of the test + prescription combination. However, in 2019/2020, the percentage of prescription alone was high and remained approximately 6%–8% from the 29th to the 35th week, although the patient number was small (Figures 2 and S1).

4 | DISCUSSION

We examined the combination patterns of medical practice for influenza by season between 2010/2011 and 2019/2020. Among all combinations of three categories (tests, diagnoses, and prescriptions), the combination of test + diagnosis + prescription was the most common except 2019/2020. This combination was 40%–50% until 2018/2019, although the percentage of the patients with any of them among population varied (11%–20%).

However, in 2019/2020 (until April), the category of test alone was approximately 10% higher than that in the other seasons. Regardless of these differences, most patients diagnosed with influenza underwent diagnostic tests and received anti-influenza drugs every season. The JAID emphasizes the importance of starting treatment early in the course of illness and recommends treatment initiation in cases of confirmed or suspected influenza. Our results suggest that the practice is consistent with this policy for patients diagnosed with influenza at the study sites. Nevertheless, these results excluded patients without a diagnosis, including those with influenza-like
symptoms, which were not accurately recorded in the database. Even so, considering a Japanese online survey reporting that 75.5% of people visited medical institution when having influenza-like illness, our study might include the majority of those with symptoms in Japan. Most patients who were prescribed drugs also underwent testing; however, patients who were prescribed anti-influenza drugs for influenza without a test were more frequently observed from the 29th week in 2019/2020. This might be explained by the influence of messaging requesting prescription based on clinical diagnosis alone from the Japanese Medical Association in March 2020 as a countermeasure for the COVID-19 pandemic. Later, in August 2020, proposals from the same association released the recommendation of diagnostic tests for both influenza and COVID-19. Therefore, this observation may have changed again in late 2020.

This study had several limitations. First, diagnosis codes may have been intentionally assigned along with diagnostic tests or prescription drugs. In addition, patients who visit medical institutions are usually willing to take treatment. These might contribute to high percentages of the combinations of diagnoses ± tests and/or prescriptions. Second, the database included few elderly people, which did not accurately reflect the Japanese population ratio. Third, we defined medical practice based on claims records; consequently, the accuracy of the results relies on the accuracy of the records. Ultimately, the claims for test and treatment are assumed to be accurately recorded because they are generated to claim medical care fees. However, prescriptions uncovered by the medical insurance system, such as prophylactics, could be included in the record if diagnosis was made to prescribe it. Fourth, the database had no information on diagnostic test results; therefore, we could not examine whether the diagnosis was based on the test results. During the epidemic, even a patient with a negative result might be diagnosed with influenza based on comprehensive judgment and then given treatment. Lastly, this study analyzed patients who visited medical institutions and did not include those who had influenza-like symptoms but not visited.

5 | CONCLUSION

This study indicates that most patients diagnosed with influenza underwent diagnostic tests and were treated with anti-influenza drugs. Further studies are needed to evaluate whether the patients were tested and treated for influenza from early onset. Since the COVID-19 pandemic began, the status of diagnosis and treatment of influenza may have changed according to social situations and recommendations from academic associations. Continuous monitoring of the actual status of treatment and diagnosis may be necessary to provide information to deal with influenza.

ACKNOWLEDGMENTS

We would like to thank Tomomi Takeshima, an employee of Milliman Inc., for writing and editorial support and Editage (www.editage.com) for English language editing, which are funded by Shionogi & Co., Ltd. This study was funded by Shionogi & Co., Ltd. and was one of the collaborative projects in the Social Cooperation Program of IT Healthcare, Graduate School of Pharmaceutical Sciences, The University of Tokyo.

AUTHOR CONTRIBUTIONS

Eiko Shimizu: Conceptualization; methodology; project administration. Kosuke Iwasaki: Conceptualization; formal analysis; methodology; software. Yoshie Hongo: Conceptualization; formal analysis; methodology; project administration. Manami Yoshida: Conceptualization; methodology. Masahiro Kinoshita: Methodology. Shinzo Hiroi: Conceptualization; methodology. Daisuke Tamura: Conceptualization; methodology.
PATIENT CONSENT STATEMENT
Informed consent was not required because this study used a database that contained anonymized data collected for secondary use.

PERMISSION TO REPRODUCE MATERIAL FROM OTHER SOURCES
This manuscript does not include any previously published material.

PEER REVIEW
The peer review history for this article is available at https://publons.com/publon/10.1111/irv.12977.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from JMDC Inc. Restrictions apply on the availability of these data, which were used under license for this study. Data are available from the authors with the permission of JMDC Inc.

ORCID
Yoshie Hongo https://orcid.org/0000-0002-0962-697X

REFERENCES
1. National Institute of Infectious diseases Ministry of Health, Labour and Welfare, Tuberculosis and Infectious Diseases Control Division. [Influenza virus in the winter of 2019/20] [Website in Japanese]. 2021; https://www.niid.go.jp/niid/ja/flu-m/590-idsc/9830-fludoko-2020.html. Accessed February 7, 2022.
2. National Institute of Infectious Disease. [What is Influenza virus?] [Website in Japanese]. 2021; https://www.niid.go.jp/niid/ja/diseases/a/flu.html. Accessed February 7, 2022.
3. Centers for Disease Control and Prevention. About flu. 2021; https://www.cdc.gov/flu/about/index.html. Accessed February 7, 2022.
4. World Health Organization. WHO public health research agenda for influenza: optimizing treatment of patients, 2017 update. 2021; https://apps.who.int/iris/bitstream/handle/10665/259887/WHO-IHM-GIP-2017.7-eng.pdf?sequence=1. Accessed February 7, 2022.
5. The Japanese Association for Infectious Disease. [Proposal from the Japanese Association for Infectious Diseases ‘About the use of anti-influenza drugs’] [Website in Japanese]. 2021; https://www.kansensho.or.jp/modules/guidelines/index.php?content_id=37. Accessed February 7, 2022.
6. Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M. Accuracy of rapid influenza diagnostic tests: A meta-analysis. Ann Intern Med. 2012;156(7):500-511.
7. Daily Surveillance of Pharmacy. [The number of influenza virus infected patients estimated by prescription of anti-influenza drug prescription] [Website in Japanese]. 2021; http://prescription.orca.med.or.jp/syndromic/kanjasuaikei/index.php. Accessed February 7, 2022.
8. ORCA Surveillance. [Influenza] [Website in Japanese]. 2021; http://infect.orca.med.or.jp/influenza/prefectures. Accessed February 7, 2022.
9. Sugaya N, Shinjo M, Mitamura K, Takahashi T. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children. J Infect. 2011;63(4):288-294.
10. Ministry of Health, Labour and Welfare. An outline of the Japanese medical system. https://www.mhlw.go.jp/bunya/iryouhoken/iryouhoken01/dl/01_eng.pdf. Accessed February 7, 2022.
11. Ministry of Health, Labour and Welfare. [Statistical classification of diseases and cause of death 2013] [Website in Japanese]. http://www.mhlw.go.jp/toukei/sippei/. Accessed February 7, 2022.
12. Tsuzuki S, Yoshihara K. The characteristics of influenza-like illness management in Japan. BMC Public Health. 2020;20(1):568.
13. Japan Medical Association. [Notification to Prefectural Medical Association for COVID-19 pandemic from Japan Medical Association. Points to keep in mind in medical care of patients with symptoms suspected of COVID-19 infection] [Document in Japanese]. 2021; https://med.or.jp/dl-med/kansen/novel_corona/2019chi_461.pdf. Accessed February 7, 2022.
14. The Japanese Association for Infectious Diseases. [Proposal from the Japanese Association for Infectious Diseases. Influenza epidemics in this winter and preparation for COVID-19 pandemic] [Document in Japanese]. 2021; https://www.kansensho.or.jp/uploads/files/guidelines/2012_teigen_influenza_covid19.pdf. Accessed February 7, 2022.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Shimizu E, Iwasaki K, Hongo Y, et al. Diagnosis and treatment of influenza based on health insurance claims between the 2010–2011 and 2019–2020 influenza seasons in Japan. Influenza Other Respi Viruses. 2022;16(4):621-625. doi:10.1111/irv.12977